Peptide News Digest

Lilly $4.5B Lebanon LEAP + Foundayo Manufacturing, Amylyx Avexitide EAP, Nature Brain Reward Circuit, Health Canada 2nd Generic Semaglutide, Orforglipron 65+

Lilly $4.5B Lebanon Indiana investment, Amylyx avexitide expanded access, Nature brain reward circuit paper, Health Canada 2nd generic semaglutide, ASC30 ECO.

10 stories · Covering industry, clinical-trials, regulatory, research

Editor's Note

Saturday rounds out a heavy week for the peptide story with several setup items for the Monday opens. Eli Lilly's May 6 ribbon-cutting at Lebanon Advanced Therapies — its first dedicated genetic medicine manufacturing facility, alongside another $4.5B committed to two more LEAP District sites for Foundayo and retatrutide production — pushed the Indiana capital commitment past $21B since 2020 and signaled a manufacturing answer to the supply-chain question that has shadowed every peptide approval since the 2022 GLP-1 shortage. The same May 6 cycle brought a Nature paper from a UVA team mapping how small-molecule GLP-1 agonists like orforglipron engage Glp1r-expressing neurons in the central amygdala to suppress dopamine release in the nucleus accumbens — a hedonic-feeding circuit distinct from the homeostatic mechanism that drives most GLP-1 weight loss. On the rare-disease side, Amylyx launched a US Expanded Access Program for up to 250 adults with post-bariatric hypoglycemia, providing access to avexitide, a first-in-class peptide GLP-1 receptor antagonist designed to block the exaggerated insulin response in PBH; the Phase 3 LUCIDITY topline reads out in Q3 2026. Health Canada approved a second generic semaglutide (Apotex's filing) on May 1 — making Canada the first G7 country with two approved Ozempic generics, with Sandoz targeting a Q3 2026 commercial launch. Two 'Beyond GLP-1' essays landed in print this month — Bloomgarden in Journal of Diabetes framing the tolerability and non-responder limits of incretin therapy, and the Frontiers in Drug Discovery April 10 review cataloging underexplored peptide-receptor systems (apelin, spexin, phoenixin, relaxin-3, osteocalcin, irisin) as the technological frontier. Ascletis' ECO 2026 poster slate emphasizes ASC30's once-monthly subQ depot 7.5% placebo-adjusted weight loss at 16 weeks; Lilly's ECO post-hoc orforglipron analysis pools 616 adults aged 65+ from ATTAIN-1 and ATTAIN-2. A 2026 Journal of Cachexia, Sarcopenia and Muscle scoping review on peptides for skeletal muscle wasting lands on a related side of the GLP-1 era — sarcopenia and incretin-associated lean-mass loss. OMI Wellbeauty's Hair Growth Peptides launch — built around the Intermediate Filament Peptide (IFP) and a clinical 47% shedding reduction — extends the consumer peptide footprint past skin into hair-loss therapeutics.

Industry

Eli Lilly Commits Additional $4.5B to Lebanon Indiana Sites, Opens First Dedicated Genetic Medicine Facility — Foundayo, Retatrutide Manufacturing Sites

Eli Lilly on May 6 cut the ribbon on Lilly Lebanon Advanced Therapies — the company's first dedicated genetic medicine manufacturing facility — and committed an additional $4.5B across two more LEAP Research and Innovation District sites in Lebanon, Indiana. The new investment supports planned production of Foundayo (orforglipron), Lilly's only FDA-approved GLP-1 pill that does not require fasting or water restrictions, and retatrutide, the triple GLP-1/GIP/glucagon agonist in seven Phase 3 trials. Total Indiana capital commitments since 2020 now exceed $21B, with the LEAP District alone totaling $18B since 2022 — the largest capital project in Indiana history. The buildout will add more than 1,000 jobs by 2027 and gives Lilly a domestic Foundayo + retatrutide supply chain independent of peptide-CDMO bottlenecks.

#eli-lilly #lebanon-indiana #leap-district #foundayo #retatrutide #manufacturing-capacity #genetic-medicine
Clinical Trials

Amylyx Launches U.S. Expanded Access Program for Avexitide — First-in-Class Peptide GLP-1 Receptor Antagonist in Post-Bariatric Hypoglycemia

Amylyx Pharmaceuticals on May 5 launched a U.S. Expanded Access Program (EAP) for up to 250 adults with post-bariatric hypoglycemia (PBH) following Roux-en-Y gastric bypass surgery. The investigational compound, avexitide, is a first-in-class peptide GLP-1 *receptor antagonist* — designed to bind GLP-1 receptors on pancreatic islet beta cells and block the exaggerated GLP-1-driven insulin response characteristic of PBH, reducing inappropriate insulin secretion and stabilizing blood glucose. Avexitide carries FDA Breakthrough Therapy Designation for both PBH and congenital hyperinsulinism, plus Orphan Drug Designation. Topline data from the pivotal Phase 3 LUCIDITY trial are anticipated in Q3 2026. The program inverts the standard GLP-1 narrative — for this population, GLP-1 signaling is the problem.

#amylyx #avexitide #post-bariatric-hypoglycemia #glp-1-antagonist #lucidity-trial #breakthrough-therapy #rare-disease
Clinical Trials

Ascletis ASC30 Posters at ECO 2026: Once-Monthly Subcutaneous Depot Shows 7.5% Placebo-Adjusted Weight Loss at 16 Weeks

Ascletis announced multiple poster presentations at the 33rd European Congress on Obesity (ECO 2026) opening May 12 in Istanbul. ASC30, a first-in-class small-molecule GLP-1R fully biased agonist developed for once-daily oral and once-monthly to once-quarterly subcutaneous dosing, will be featured across formulation, PK, and clinical-data posters. The Phase 2 13-week study previously reported 7.7% placebo-adjusted weight loss at 60 mg oral dosing; the once-monthly subQ depot formulation achieved 7.5% placebo-adjusted weight loss at 16 weeks after three monthly doses, with topline T2D Phase 2 data expected Q3 2026. The subQ depot angle directly challenges Pfizer's MET-097i monthly thesis with a different mechanism (small-molecule GLP-1R biased agonist vs ultra-long-acting peptide).

#ascletis #asc30 #eco-2026 #oral-glp-1 #monthly-injectable #small-molecule-glp-1 #biased-agonism
Regulatory

Health Canada Approves Second Generic Semaglutide (Apotex) on May 1 — Canada Becomes First G7 Country With Two Approved Ozempic Generics

Health Canada announced May 1 approval of a second generic semaglutide injection, filed by Canadian-based Apotex as a generic version of Novo Nordisk's Ozempic. The April 28, 2026 first approval (Dr. Reddy's Laboratories) was followed three days later by the Apotex green light, making Canada the first G7 country with two approved generic semaglutide products. Health Canada is currently reviewing seven additional generic submissions. Patent context: Canadian patent protection lapsed earlier than expected after a Novo Nordisk maintenance-fee issue. Sandoz separately targets a Q3 2026 commercial launch and the company has projected 45-90% price reductions versus brand-name Ozempic. US patent protection runs through December 2031.

#health-canada #generic-semaglutide #apotex #sandoz #novo-nordisk #patent-expiry #g7
Research

Frontiers in Drug Discovery (April 10): "Beyond GLP-1" Review Maps Underexplored Peptide-Receptor Systems as Next Therapeutic Frontier

A Frontiers in Drug Discovery review (April 10, 2026) catalogs underexplored peptide-receptor systems that the authors argue failed not for biological reasons but because of technical and conceptual barriers solvable with modern peptide engineering. Coverage spans metabolic and energy-balance peptides (apelin, spexin), appetite-regulating systems (peptide YY, oxyntomodulin), bone-muscle-fat crosstalk mediators (osteocalcin, irisin), and neuroendocrine-immune-metabolic peptides (phoenixin, relaxin-3). The argument: lessons from GLP-1 — stabilization, conjugation, and dosing innovation — now make these orphan receptor systems tractable. Companion essay from Bloomgarden in the Journal of Diabetes (2026, vol 18 e70204) frames the same opportunity from the clinical side, citing GLP-1 tolerability ceilings and the 10-20% non-responder problem that creates room for the next wave.

#frontiers #beyond-glp-1 #apelin #spexin #irisin #phoenixin #peptide-receptor-systems #drug-discovery
Research

Nature (May 6): Brain Reward Circuit Inhibited by Next-Generation Weight-Loss Drugs — UVA Team Shows Small-Molecule GLP-1s Engage Central Amygdala Glp1r+ Neurons

A Nature paper published May 6 from a University of Virginia team developed humanized GLP1R mouse models to investigate how small-molecule GLP1R agonists — including orforglipron (Foundayo) — regulate feeding behavior. Beyond canonical hypothalamic and hindbrain networks that control metabolic homeostasis, the team showed these oral compounds recruit a discrete population of Glp1r-expressing neurons in the central amygdala and selectively suppress consumption of palatable foods by reducing dopamine release in the nucleus accumbens — a parallel hedonic-feeding circuit distinct from the homeostatic mechanism that drives most GLP-1 weight loss. The work explains why patients on small-molecule oral GLP-1s often report reduced food cravings and pleasure-driven eating, and identifies a neural circuit with implications for substance-use disorder and binge eating beyond obesity.

#nature #orforglipron #small-molecule-glp-1 #brain-reward-circuit #central-amygdala #hedonic-feeding #uva #mechanism
Industry

OMI Wellbeauty Launches Hair Growth Peptides Built Around Intermediate Filament Peptide (IFP), Clinical Study Shows 47% Less Shedding at 90 Days

OMI Wellbeauty (founder Naomi Whittel) launched a Hair Growth Peptides supplement line in May 2026, anchored by the Intermediate Filament Peptide (IFP) — a bioactive peptide formulated to support keratin networks in hair follicles and collagen IV production at the root. The double-blind, placebo-controlled 90-day clinical study reported 47% reduction in hair shedding with no significant side effects. The launch sits alongside Neurogan's 2% GHK-Cu body care and Auro Wellness's copper-tripeptide serum as part of the cosmetic and consumer-supplement peptide wave that has been accelerating into the July 2026 PCAC meeting. Unlike compounded peptides, OMI's product is a dietary supplement — not an FDA-approved drug — but the clinical-evidence framing distinguishes it from the broader unregulated peptide-supplement market.

#omi-wellbeauty #hair-growth-peptides #ifp #cosmetic-peptides #supplements #consumer-products
Research

Journal of Cachexia, Sarcopenia and Muscle (2026): Scoping Review Maps Peptides for Skeletal Muscle Wasting — Relevant to GLP-1-Era Lean-Mass Concerns

A 2026 scoping review in the Journal of Cachexia, Sarcopenia and Muscle catalogs peptides studied as therapeutic candidates and biomarkers in skeletal muscle wasting — covering sarcopenia, cancer cachexia, and ICU-related atrophy. The review documents MIF1/MIF2 myostatin peptide inhibitors, cachexia-targeting platform peptides, and the broader role of GH-axis peptides (CJC-1295, ipamorelin, tesamorelin) in muscle homeostasis. The clinical urgency lands harder now than it did pre-2024: Nature Reviews Endocrinology recently flagged sarcopenia and frailty as under-recognized GLP-1 receptor agonist side effects, with up to 40% of GLP-1-induced weight loss attributable to lean mass in the highest-loss patients. The review surfaces non-GLP-1 peptide candidates that could be paired with incretin therapy to protect muscle.

#sarcopenia #muscle-wasting #cachexia #glp-1-side-effects #myostatin #cjc-1295 #tesamorelin #scoping-review
Research

Bloomgarden in Journal of Diabetes: "Beyond GLP-1" — Tolerability Ceilings and Non-Responder Limits Drive the Next Wave

Bloomgarden's commentary in the Journal of Diabetes (2026, vol 18, e70204) frames the clinical case for moving past first-generation GLP-1 agonists, focusing on two limits: gastrointestinal intolerance that forces dose reduction or discontinuation in 15-30% of patients depending on agent and titration, and a non-responder problem where roughly 10-20% of treated individuals fail to reach the expected weight-loss range. With 12% of US adults reported to have at least temporarily received a GLP-1 agonist, the population-level stakes are large. The commentary lands alongside the Frontiers Drug Discovery 'Beyond GLP-1' review as one of two academic pieces this month formalizing the post-incretin research agenda — and aligns with the AstraZeneca ASCEND triple-mechanism thesis, the petrelintide + enicepatide combination program, and Lilly's quintuple agonist disclosed for ADA 2026.

#bloomgarden #journal-of-diabetes #beyond-glp-1 #glp-1-side-effects #non-responders #obesity-treatment
Clinical Trials

Lilly ECO 2026 Preview: Orforglipron Post-Hoc Subgroup Analysis in Adults Aged 65+ Drawn from ATTAIN-1 + ATTAIN-2 Phase 3 Pool

A post-hoc subgroup analysis of Eli Lilly's orforglipron (Foundayo) in adults aged 65 and older, drawn from the ATTAIN-1 and ATTAIN-2 Phase 3 programs, will be presented at ECO 2026 in Istanbul May 12-15. The analysis pools 616 randomized participants (613 treated) — 118 on 6 mg, 135 on 12 mg, 146 on 36 mg orforglipron, and 214 placebo — across patients with and without type 2 diabetes. The geriatric data set addresses a long-standing clinical gap: incretin trials have systematically underenrolled adults over 65, the population most affected by obesity-related comorbidities and the most likely to face polypharmacy-related GI tolerability concerns. Lead author Dr. Deborah Horn (UTHealth Houston McGovern Medical School). The presentation is among the ECO 2026 abstracts that will shape geriatric prescribing patterns for the first FDA-approved GLP-1 pill that does not require fasting or water restrictions.

#orforglipron #foundayo #eli-lilly #eco-2026 #attain-1 #attain-2 #geriatric #older-adults #post-hoc-analysis